AstraZenecaAZN
AZN
About: A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Employees: 94,300
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
39% more call options, than puts
Call options by funds: $491M | Put options by funds: $354M
7% more first-time investments, than exits
New positions opened: 157 | Existing positions closed: 147
0.85% more ownership
Funds ownership: 32.25% [Q3] → 33.1% (+0.85%) [Q4]
1% less repeat investments, than reductions
Existing positions increased: 421 | Existing positions reduced: 424
1% less funds holding
Funds holding: 1,212 [Q3] → 1,196 (-16) [Q4]
13% less capital invested
Capital invested by funds: $39B [Q3] → $34.1B (-$4.9B) [Q4]
19% less funds holding in top 10
Funds holding in top 10: 16 [Q3] → 13 (-3) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for AZN.
Financial journalist opinion
Based on 41 articles about AZN published over the past 30 days
Neutral
Business Wire
23 hours ago
AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will present the latest clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in San Francisco, CA from May 16 to 21, 2025. With more than 75 abstracts, including eight late-breakers, the Company continues to drive innovation and address unmet needs in care across all severities of asthma, chronic obstructive pulmonary disease (COPD).
Neutral
CNBC Television
1 day ago
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
Positive
Zacks Investment Research
4 days ago
How Much Upside is Left in Astrazeneca (AZN)? Wall Street Analysts Think 27.89%
The consensus price target hints at a 27.9% upside potential for Astrazeneca (AZN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
Business Wire
4 days ago
IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the POTOMAC Phase III trial showed one year of treatment with AstraZeneca's IMFINZI® (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) compared to BCG induction and maintenance therapy alone. The trial was not statistically pow.
Positive
Proactive Investors
5 days ago
AstraZeneca's Imfinzi delays bladder cancer return in high-risk patients
AstraZeneca PLC (LSE:AZN) has reported encouraging results from a late-stage trial of its cancer immunotherapy Imfinzi, which significantly extended the time patients with early-stage bladder cancer lived without their disease coming back or getting worse. The data, released Friday, come from the company's phase III POTOMAC trial and mark a potential breakthrough for patients with high-risk non-muscle-invasive bladder cancer, a form of the disease that accounts for the majority of bladder cancer diagnoses and has a stubborn tendency to return.
Negative
Proactive Investors
1 week ago
AstraZeneca and GSK slide as Trump and RFK appoint new FDA vaccine chief
Shares in AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK) on the back of an appointment by Donald Trump and his health secretary Robert F Kennedy Jnr of a key position at the US drug regulator. Vinay Prasad, a vaccine sceptic like Kennedy, has been made head of the US Food and Drug Administration's Center for Biologics Evaluation and Research.
Neutral
Zacks Investment Research
1 week ago
AZN or ARGX: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Astrazeneca (AZN) or argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?
Positive
Reuters
1 week ago
AstraZeneca's Breztri meets main goals of late-stage asthma trials
Anglo-Swedish drugmaker AstraZeneca on Friday said its inhaler therapy Breztri Aerosphere met all the main goals of two late-stage trials in patients with uncontrolled asthma.
Positive
Proactive Investors
1 week ago
AstraZeneca has plenty coming down the pipeline to appease the bears
AstraZeneca PLC (LSE:AZN) investors looking beyond the short-term noise of Medicare reform and currency headwinds may want to focus on a growing pipeline of clinical catalysts and a valuation that UBS believes underplays the company's longer-term potential. The bank retains its 'buy' rating with a price target of 14,200p, offering more than 30% upside from the current share price of around 10,600p.
Positive
CNBC International TV
2 weeks ago
AstraZeneca has built resilient supply chains in U.S., China: CEO
AstraZeneca CEO Pascal Soriot discusses earnings, the potential trade tariff impact on the business and the outlook for the firm's key markets.
Charts implemented using Lightweight Charts™